BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

451 related articles for article (PubMed ID: 25878177)

  • 1. Perampanel efficacy and tolerability with enzyme-inducing AEDs in patients with epilepsy.
    Gidal BE; Laurenza A; Hussein Z; Yang H; Fain R; Edelstein J; Kumar D; Ferry J
    Neurology; 2015 May; 84(19):1972-80. PubMed ID: 25878177
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Concentration-effect relationships with perampanel in patients with pharmacoresistant partial-onset seizures.
    Gidal BE; Ferry J; Majid O; Hussein Z
    Epilepsia; 2013 Aug; 54(8):1490-7. PubMed ID: 23772853
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and tolerability of adjunct perampanel based on number of antiepileptic drugs at baseline and baseline predictors of efficacy: A phase III post-hoc analysis.
    Glauser T; Laurenza A; Yang H; Williams B; Ma T; Fain R
    Epilepsy Res; 2016 Jan; 119():34-40. PubMed ID: 26656783
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of pooled phase III trials of adjunctive perampanel for epilepsy: Impact of mechanism of action and pharmacokinetics on clinical outcomes.
    Kwan P; Brodie MJ; Laurenza A; FitzGibbon H; Gidal BE
    Epilepsy Res; 2015 Nov; 117():117-24. PubMed ID: 26448264
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: results of randomized global phase III study 305.
    French JA; Krauss GL; Steinhoff BJ; Squillacote D; Yang H; Kumar D; Laurenza A
    Epilepsia; 2013 Jan; 54(1):117-25. PubMed ID: 22905857
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Final safety, tolerability, and seizure outcomes in patients with focal epilepsy treated with adjunctive perampanel for up to 4 years in an open-label extension of phase III randomized trials: Study 307.
    Krauss GL; Perucca E; Kwan P; Ben-Menachem E; Wang XF; Shih JJ; Patten A; Yang H; Williams B; Laurenza A
    Epilepsia; 2018 Apr; 59(4):866-876. PubMed ID: 29574701
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of perampanel in patients with drug-resistant partial seizures after conversion from double-blind placebo to open-label perampanel.
    Montouris G; Yang H; Williams B; Zhou S; Laurenza A; Fain R
    Epilepsy Res; 2015 Aug; 114():131-40. PubMed ID: 26088896
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjunctive perampanel for refractory partial-onset seizures: randomized phase III study 304.
    French JA; Krauss GL; Biton V; Squillacote D; Yang H; Laurenza A; Kumar D; Rogawski MA
    Neurology; 2012 Aug; 79(6):589-96. PubMed ID: 22843280
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized phase III study 306: adjunctive perampanel for refractory partial-onset seizures.
    Krauss GL; Serratosa JM; Villanueva V; Endziniene M; Hong Z; French J; Yang H; Squillacote D; Edwards HB; Zhu J; Laurenza A
    Neurology; 2012 May; 78(18):1408-15. PubMed ID: 22517103
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term effects of adjunctive perampanel on cognition in adolescents with partial seizures.
    Piña-Garza JE; Lagae L; Villanueva V; Renfroe JB; Laurenza A; Williams B; Kumar D; Meador KJ
    Epilepsy Behav; 2018 Jun; 83():50-58. PubMed ID: 29653338
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of adjunctive perampanel in adolescent patients with epilepsy: Post hoc analysis of six randomized studies.
    Piña-Garza JE; Rosenfeld W; Saeki K; Villanueva V; Yoshinaga H; Patten A; Williams B; Malhotra M
    Epilepsy Behav; 2020 Mar; 104(Pt A):106876. PubMed ID: 31954998
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of perampanel in adolescent patients with drug-resistant partial seizures in three double-blind, placebo-controlled, phase III randomized clinical studies and a combined extension study.
    Rosenfeld W; Conry J; Lagae L; Rozentals G; Yang H; Fain R; Williams B; Kumar D; Zhu J; Laurenza A
    Eur J Paediatr Neurol; 2015 Jul; 19(4):435-45. PubMed ID: 25823975
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Perampanel, a selective, noncompetitive α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist, as adjunctive therapy for refractory partial-onset seizures: interim results from phase III, extension study 307.
    Krauss GL; Perucca E; Ben-Menachem E; Kwan P; Shih JJ; Squillacote D; Yang H; Gee M; Zhu J; Laurenza A
    Epilepsia; 2013 Jan; 54(1):126-34. PubMed ID: 22905878
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of adjunctive perampanel for the treatment of refractory partial seizures: a pooled analysis of three phase III studies.
    Steinhoff BJ; Ben-Menachem E; Ryvlin P; Shorvon S; Kramer L; Satlin A; Squillacote D; Yang H; Zhu J; Laurenza A
    Epilepsia; 2013 Aug; 54(8):1481-9. PubMed ID: 23663001
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjunctive perampanel in partial-onset seizures: Asia-Pacific, randomized phase III study.
    Nishida T; Lee SK; Inoue Y; Saeki K; Ishikawa K; Kaneko S
    Acta Neurol Scand; 2018 Apr; 137(4):392-399. PubMed ID: 29250772
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adverse effects and safety profile of perampanel: a review of pooled data.
    Rugg-Gunn F
    Epilepsia; 2014 Jan; 55 Suppl 1():13-5. PubMed ID: 24400692
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term tolerability, safety and efficacy of adjunctive perampanel in the open-label, dose-ascending Study 231 and extension Study 233 in Japanese patients with epilepsy.
    Usui N; Akamatsu N; Nakasato N; Ohnishi A; Kaneko S; Hiramatsu H; Saeki K; Miyagishi H; Inoue Y
    Seizure; 2018 Nov; 62():26-32. PubMed ID: 30267941
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tolerability and safety of perampanel: two randomized dose-escalation studies.
    Krauss GL; Bar M; Biton V; Klapper JA; Rektor I; Vaiciene-Magistris N; Squillacote D; Kumar D
    Acta Neurol Scand; 2012 Jan; 125(1):8-15. PubMed ID: 21883097
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel treatment options for epilepsy: focus on perampanel.
    Franco V; Crema F; Iudice A; Zaccara G; Grillo E
    Pharmacol Res; 2013 Apr; 70(1):35-40. PubMed ID: 23287426
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Perampanel efficacy and safety by gender: Subanalysis of phase III randomized clinical studies in subjects with partial seizures.
    Vazquez B; Yang H; Williams B; Zhou S; Laurenza A
    Epilepsia; 2015 Jul; 56(7):e90-4. PubMed ID: 26096637
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.